Live attenuated rotavirus vaccine

Phase 2Vaccine

GSK

Live attenuated rotavirus vaccine is one of 20 biologic programs targeting Gastroenteritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastroenteritisActive, not recruiting

GastroenteritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

32 competitors in Gastroenteritis

#DrugCompanyPhaseTrials

Zofran

Novartis

Approved

8 2

Cipro

Bayer

Approved

—3

Reglan

IIstituto Clinico Humanitas

Approved

—4

Hyoscine-N-Butylbromide

Boehringer Ingelheim

Approved

2 5

Dimenhydrinate

SSt. Justine's Hospital

Approved

1 6

Rotarix ™

GSK

Phase 3

1 7

Prulifloxacin

Merck & Co.

Phase 3

1 8

Domperidone

Johnson & Johnson

Phase 3

1 9

Xolair

Roche

Phase 2

1 10

Papaverine

WWestern Galilee Hospital-Nahariya

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastroenteritis2 trials

Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis

Completed· GSK logo

GSK·Phase 2·NCT00137930·250 enrolled

Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis

Completed· GSK logo

GSK·Phase 3·NCT00134732·150 enrolled

Immunogenicity2 trials

Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India

Completed· GSK logo

GSK·Phase 3·NCT00289172·360 enrolled

Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants

Completed· GSK logo

GSK·Phase 3·NCT00169455·450 enrolled

Vaccine1 trial

A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults

Completed· GSK logo

GSK·Phase 2·NCT00239577·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Live attenuated rotavirus vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Live attenuated rotavirus vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Live attenuated rotavirus vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: GSK

Live attenuated rotavirus vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastroenteritis2 trials

Immunogenicity2 trials

Vaccine1 trial

References

Drug Info

Quick Facts

Related News